Suppr超能文献

首次未获得处方药物:心血管药物治疗的主要不依从性。

Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.

机构信息

Institute of Pharmacy, Freie Universität Berlin, Kelchstraße 31, 12169, Berlin, Germany.

Drug Commission of German Pharmacists (AMK), Heidestraße 7, 10557, Berlin, Germany.

出版信息

Clin Res Cardiol. 2024 Aug;113(8):1103-1116. doi: 10.1007/s00392-023-02230-3. Epub 2023 May 20.

Abstract

Primary medication non-adherence describes the situation when a first prescription for a new medication is never filled. Primary non-adherence is an important, yet understudied aspect of reduced effectiveness of pharmacotherapy. This review summarizes the frequency, impact, reasons, predictors, and interventions regarding primary non-adherence to cardiovascular/cardiometabolic drugs. The current literature reveals a high prevalence of primary non-adherence. The individual risk of primary non-adherence is determined on multiple factors, e.g., primary non-adherence of lipid-lowering drugs is higher compared to antihypertensive medications. However, the overall rate of primary non-adherence is > 10%. Additionally, this review identifies specific areas for research to better understand why patients forgo evidence-based beneficial pharmacotherapy and to explore targeted interventions. At the same time, measures to reduce primary non-adherence-once proven to be effective-may represent an important new opportunity to reduce cardiovascular diseases.

摘要

主要药物不依从性描述的是一种新处方药物从未被配药的情况。主要不依从性是药物治疗效果降低的一个重要但研究不足的方面。这篇综述总结了心血管/心脏代谢药物主要不依从性的频率、影响、原因、预测因素和干预措施。目前的文献显示主要不依从性的发生率很高。个体发生主要不依从性的风险由多种因素决定,例如,与降压药物相比,降脂药物的主要不依从性更高。然而,总体主要不依从性的比率>10%。此外,本综述确定了具体的研究领域,以更好地了解为什么患者会放弃基于证据的有益药物治疗,并探索有针对性的干预措施。同时,一旦证明减少主要不依从性是有效的措施,可能代表减少心血管疾病的一个重要新机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/11269373/6421f0189fa9/392_2023_2230_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验